left-arrow right-arrow pinterest facebook google_plus linkedin

Head and Neck Cancer Trials

The following listings are our current trials. If you have questions or want to learn more about the trial, please contact us and provide the Methodist Health System Trial Code listed with the description.


Alliance A091302

Status: Recruiting | Phase II

Official Title: Randomized Phase II Study of Sorafenib With or Without Everolimus in Patients with Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer

Study Purpose: To determine if adding everolimus, a chemotherapy drug, to the standard treatment for radioactive iodine refractory Hurthle thyroid cancer will control the cancer longer than the standard treatment alone. Learn more.


ECOG-ACRIN EA3132

Status: Recruiting | Phase II

Official Title: Testing The Addition Of Chemotherapy Drug, Cisplatin, To Usual Radiation Therapy For Patients With Head And Neck Cancer

Study Purpose: The purpose of this study is to compare two treatment approaches currently used after surgery for head and neck cancer. One approach is to administer radiation therapy alone.  A second approach is to administer radiation therapy along with the chemotherapy drug, cisplatin. Learn more


Exelixis XL184-311

Status: Recruiting | Phase III 

Official Title: A phase 3, randomized, double-blind, placebo-controlled study of cabozantinib (XL184) in subjects with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy.

Study Purpose: The purpose of this study is to evaluate the effect of cabozantinib compared with placebo on progression free survival (PFS) and objective response rate (ORR) in subjects with Radioiodine-Refractory Differentiated Thyroid Cancer (DTC) who have progressed after prior VEGFR-Targeted therapy. Learn more


MECC HN01 - HPV De-escalated Protocol

Status: Recruiting | Phase: NA

Official Title: De-escalation Protocol of HPV Mediated Oropharyngeal Squamous Cell Carcinoma Based on the American Joint Committee on Cancer Care (AJCC) 8th Edition Staging Manual

Study Purpose: HPV positive head and neck cancer has been shown to respond very well to treatment and, as a result, the head and neck cancer staging system was updated to better reflect how HPV cancers respond to treatment.  So the purpose of this study is to evaluate the effects of treating patients with Human Papilloma Virus (HPV) positive head and neck cancer with less treatment based on the updated head and neck cancer staging system. Learn more.


NRG HN001

Status: Recruiting | Phase II and III

Official Title: Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)

Study Purpose: To compare the standard treatment for nasopharyngeal cancer with the drug combination gemcitabine and paclitaxel to see if patients do better and live longer.  This is also testing if directing treatment using a blood test to look for the Epstien Bar Virus will result in patients doing better and not needing as much treatment. Learn more.


RTOG 1008

Status: Recruiting | Phase II and III

Official Title: A Randomized Phase II Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors

Study Purpose: To compared the effects of radiation and chemotherapy with radiation alone on patients with salivary gland cancer that was removed surgically to find out which is better at reducing the risk of the cancer coming back. Learn more.


RTOG 1216

Status: Suspended | Phase II/III 

Official Title: Randomized phase II/III trial of surgery and postoperative radiation delivered with concurrent cisplatin versus docetaxel versus docetaxel and cetuximab for high-risk squamous cell cancer of the head and neck.

Study Purpose: The purpose of this study is to find out what effects, good and/or bad, treatment has on you and your cancer.  Learn more